argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
|Articles|August 12, 2020
CTS Bioprocessing Acquires Sani-Tech West Companies and Rebrands as SaniSure
Author(s)BioPharm International Editors
The companies will work to establish an operational footprint across North America and Europe that will offer customers supply chain assurance for a combined portfolio of leading solutions.
Advertisement
CTS Bioprocessing, a single-use bioprocessing technology company, announced on August 11, 2020 that it is acquiring Sani-Tech West Companies and rebranding from CTS Bioprocessing to SaniSure.
According to a CTS press release, the companies will work to establish an operational footprint across North America and Europe that will offer customers supply chain assurance for a combined portfolio of leading solutions, supported by a leading network of global distribution partners. The new company will provide solutions for fluid path technologies, including PharmaTainer bottles and carboys, Cap2v8 solutions, aSURE fittings, Bio-Ease clamps, Mixed4Sure closed Carboy Mixing systems, Gama stable stir bars, and a range of silicone tubing and other elastomeric solutions.
“We are excited to work with 3i and the CTS team,” said Richard Shor, founder and CEO of Sani-Tech West, in the press release. “We have a shared vision for the future, which was critical to our decision to join the group. Together, our expanded portfolio of innovative product offerings, extensive design and manufacturing capabilities, and our broadened geographic footprint will help us to become an even stronger partner to our customers.”
Source:
Advertisement
Related to this article
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5